

FACSIMILE

Date: January 28, 2002

To: Examiner G. Bansal
Art Unit 1640

Facsimile No.: 703.308.4242
703.305.3014

Telephone No.:

From: Nancy J. Axelrod

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201 (U.S.A.)
(Fax: 703-243-6410)

Writer's Direct Dial: 703.812.5304

Writer's Internet Address: axelrod@mwzb.com

Re: USSN 08/817,595

Pharmaceutical Composition for Stimulation of the Immune System

Our Ref: MARGI 15

Total No. of Pages: 8; if you do not receive all pages, please call 703-243-6333.



RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

Information contained in this facsimile communication may contain privileged and confidential information and is intended solely for the use of the addressee listed above. If you are neither the intended recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original document to us at our cost. Thank you.



IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In application of

Angela TURIANO

Serial No. 08/817,595

Filed: April 22, 1997

For: PHARMACEUTICAL COMPOSITION FOR STIMULATION OF THE IMMUNE SYSTEM

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

In response to the Office Action dated August 28, 2001, please amend the above-identified application as indicated below and consider the remarks which follow:

CERTIFICATION OF FACSIMILE TRANSMISSION
I HEREBY CERTIFY THAT THIS PAPER IS BEING
FACSIMILE TRANSMITTED TO THE PATENT AND TRADEMARK
OFFICE ON THE DATE SHOWN BELOW.

TYPE OR PRINT NAME OF PERSON SIGNING CERTIFICATION

Nancy Axelrod
SIGNATURE Nancy Axelrod DATE 1/28/02

IN THE CLAIMS:

Please amend claims 25, 34, 36 and 39 as follows:

25. (Amended) A kit useful for the treatment of a carcinoma in a patient, comprising at least two containers, each comprising an extract from an animal tissue, serum or cell source different from that of the other container, wherein said extracts

- a) comprise allogeneic or xenogeneic MHC molecules;
- b) are prepared by a) homogenizing the tissue, serum or cell source in the presence of NP40, or b) treating said source with an acid, or c) treating said source with a proteolytic enzyme; and
- c) are each effective to reduce the number of tumor cells in the patient compared to the number of tumor cells if the patient is not so treated.